Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia.

• Main Authors: Saskia van Henten (Author), Annisa Befekadu Tesfaye (Author), Seid Getahun Abdela (Author), Feleke Tilahun (Author), Helina Fikre (Author), Jozefien Buyze (Author), Mekibib Kassa (Author), Lieselotte Cnops (Author), Myrthe Pareyn (Author), Rezika Mohammed (Author), Florian Vogt (Author), Ermias Diro (Author), Johan van Griensven (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

<h4>Background</h4>Cutaneous leishmaniasis (CL) in Ethiopia, caused by Leishmania aethiopica, is often severe and hard to treat compared to CL caused by other species elsewhere. Miltefosine is the only oral anti-leishmanial drug, with a favorable side-effect profile compared to routinely...